Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the FDA has approved Dupixent for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
https://thefly.com/landingPageNews.php?id=2877393
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.